Deutsche Bank AG Has $7.62 Million Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Deutsche Bank AG trimmed its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 18.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 273,811 shares of the company's stock after selling 61,807 shares during the period. Deutsche Bank AG owned about 0.39% of Akero Therapeutics worth $7,617,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in AKRO. Summit Investment Advisors Inc. lifted its stake in Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock valued at $197,000 after acquiring an additional 450 shares in the last quarter. Hsbc Holdings PLC raised its holdings in shares of Akero Therapeutics by 8.5% in the fourth quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock valued at $220,000 after purchasing an additional 621 shares during the last quarter. Handelsbanken Fonder AB lifted its position in shares of Akero Therapeutics by 5.0% in the fourth quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock worth $584,000 after purchasing an additional 1,000 shares in the last quarter. Swiss National Bank boosted its holdings in Akero Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 95,600 shares of the company's stock worth $2,660,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Akero Therapeutics by 1.3% during the fourth quarter. Rhumbline Advisers now owns 105,686 shares of the company's stock worth $2,940,000 after purchasing an additional 1,310 shares during the last quarter.

Analysts Set New Price Targets

AKRO has been the topic of several recent research reports. Citigroup lowered their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Bank of America upgraded Akero Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Canaccord Genuity Group boosted their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. HC Wainwright increased their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Finally, Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $82.33.

Insiders Place Their Bets

In other Akero Therapeutics news, CEO Andrew Cheng sold 30,000 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $41.77, for a total transaction of $1,253,100.00. Following the transaction, the chief executive officer now owns 656,062 shares in the company, valued at $27,403,709.74. This trade represents a 4.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jonathan Young sold 607 shares of Akero Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $27,242.16. Following the completion of the transaction, the chief operating officer now directly owns 200,540 shares of the company's stock, valued at $9,000,235.20. This represents a 0.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 219,208 shares of company stock worth $9,113,294 in the last quarter. 7.94% of the stock is currently owned by corporate insiders.

Akero Therapeutics Stock Performance

NASDAQ AKRO traded down $1.12 during trading on Friday, reaching $47.86. 227,974 shares of the company's stock were exchanged, compared to its average volume of 947,772. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The stock has a market capitalization of $3.81 billion, a P/E ratio of -12.72 and a beta of -0.12. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The business has a 50 day moving average price of $40.92 and a 200-day moving average price of $38.17.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $1.91. Sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.